Concepedia

Daniel Eriksson

DE

Statistics

Publications

17

Citations

727

H-Index

13

Active since

2016

Affiliations

Bayer (Germany)(Current)

Hartford Hospital

University of Connecticut

Hartford Financial Services (United States)

SouthCoast Health

Daniel Eriksson is an author at Bayer (Germany) specializing in medicine, pharmacotherapy, and cardiology.

ORCID

Publications per year

2016–2023

17

Publications

17

Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis

Craig I Coleman, Reinhold Kreutz, Nitesh Sood et al. · The American Journal of Medicine · 2019 · 123 citations

, , +14

Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis

Nicole Hannemann, Shan Cao, Daniel Eriksson et al. · Journal of Clinical Investigation · 2019 · 114 citations · Full text

, , +17

Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia

Daniel Eriksson, David Goldsmith, S Teitsson et al. · BMC Nephrology · 2016 · 102 citations · Full text

, , +17

Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes

Adrían V. Hernández, G. Bradley, Mohammad Khan et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 2019 · 67 citations

, , +16

Rivaroxaban’s Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis

Craig I Coleman, Reinhold Kreutz, Nitesh Sood et al. · Clinical and Applied Thrombosis/Hemostasis · 2019 · 59 citations · Full text

, , +17

1–5 of 17